Orexigen Therapeutics, Inc., a biopharmaceutical operator, filed for Chapter 11 bankruptcy restructuring on Mar. 12, 2018. Its poor financial condition was highlighted by it's FRISK® score that landed firmly in the "red zone" for more than a year. Statistically, 96% of American public companies that go bankrupt pass through this high-risk category before filing.
This Bankruptcy Case Study will illustrate key factors that contributed to the collapse of the company. CreditRiskMonitor addresses concerns mentioned within the MD&A as well as relevant financial metrics. Fundamentally, its ability to generate sales was dependant on the commercial success of its only product, Contrave®. Simultaneously, it's unrestrained spending and high financial leverage ultimately led to debt covenant compliance risk.
If you are interested in protecting your portfolio against risk, we invite you to schedule a personalized demo with us to learn more about our offerings.
About Bankruptcy Case Studies
CreditRiskMonitor® Bankruptcy Case Studies provide post-filing analyses of public company bankruptcies. Our case studies educate subscribers about methods they can apply to assess bankruptcy risk using our proprietary FRISK® score, robust financial database, and timely news alerts.
In nearly every case, a low FRISK® score gave our subscribers early warning of financial distress within a one-year time horizon. Our proprietary FRISK® score predicts bankruptcy risk at public companies with 96% accuracy. The score is formulated by a number of indicators including stock market capitalization and volatility, financial ratios, bond agency ratings from Moody’s, Fitch and DBRS, and crowdsourced behavioral data from a subscriber group that includes 35% of the Fortune 1000 and thousands more worldwide.
Whether you are new to credit analysis or have decades of experience under your belt, CreditRiskMonitor® Bankruptcy Case Studies offer unique insights into the business and financial decline that precedes bankruptcy.